Medical Decision Making · 2002 · 322 citations · 17 references
PharmacyPharmacoeconomicsPharmacotherapyCost-effectiveness AnalysisHealth EconomicsPharmacoeconomic ModelingCost-effectiveness ModelingEconomic EvaluationGastroesophageal Reflux DiseaseHealthcare Cost AnalysisModel-based Economic EvaluationPharmacoeconomic EvaluationCalibration Of Cost-effectiveness ModelsCost-effectivenessCost-effectiveness Of TherapyHealth Economic Decision ModelingMethods Of Economic EvaluationProbabilistic AnalysisTreatment StrategiesValidation Of Cost-effectiveness Models
When choosing between mutually exclusive treatment options, it is common to construct a cost-effectiveness frontier on the cost-effectiveness plane that represents efficient points from among the treatment choices. Treatment options internal to the frontier are considered inefficient and are excluded either by strict dominance or by appealing to the principle of extended dominance. However, when uncertainty is considered, options excluded under the baseline analysis may form part of the cost-effectiveness frontier. By adopting a Bayesian approach, where distributions for model parameters are specified, uncertainty in the decision concerning which treatment option should be implemented is addressed directly. The approach is illustrated using an example from a recently published cost-effectiveness analysis of different possible treatment strategies for gastroesophageal reflux disease.It is argued that probabilistic analyses should be encouraged because they have potential to quantify the strength of evidence in favor of particular treatment choices.
17
Costs, effects and C/E‐ratios alongside a clinical trial
Ben A. van Hout, Maiwenn Al, Gilad S. Gordon et al. · Health Economics · 1994 · 981 citations
Introduction to Statistical Decision Theory.
Mark J. Schervish, John W. Pratt, Howard Raiffa et al. · Journal of the American Statistical Association · 1996 · 717 citations